Moleculin Biotech, Inc.

Greetings and welcome to the Molecular and Biotech Quarterly Update Conference Call and Webcast. At this time, all participants are in listen-only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may be placed into question queue at any time by pressing star one on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Janine Thomas, Investor Relations. Please go ahead, Janine.

Thank you, Kevin. Good morning and welcome, everyone. At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the Federal Securities Laws and are based on Moleculin's current expectations, and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports Moleculin files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys, and other data obtained from third-party sources and the company's own estimates and research. While the company believes these third-party sources to be reliable as of the date of this presentation, it does not independently verify and makes no representation as to the adequacy, fairness, accuracy, or completeness of of that any independent source or verified any information obtained from third party source. Any data discussed regarding clinical trials and progress are considered preliminary and subject to change. This morning joining us on our call from Moleculin's leadership team are Walter Klempp, Chairman and Chief Executive Officer, Dr. John Paul Ramack, Senior Chief Medical Officer, and Jonathan Foster, Executive Vice President and Chief Financial Officer. I would now like to turn the call over to Mr. Klimt. Wally, please proceed.

Thank you, Janine. Well, investors who've been following our presentations are not new to this, but we are resolute in our belief that our current market cap is nowhere close to reflecting the value of a phase three company like Moleculin, especially in light of how much risk we believe we have removed from the pathway to approval. Ultimately, we believe that just creates more opportunity for investors today. And I'm confident that as our miracle trial unfolds, the magnitude of this opportunity will become more apparent. If you're new to molecular and asking why this opportunity even exists, we believe that for nearly a decade now, the AML space has been betting on a big payoff from targeted therapies. Excuse me. But the reality is that these new targeted therapies simply haven't delivered. In fact, they've been a big disappointment. And it's evidenced by the fact that venetoclax, which is a non-targeted chemotherapy, has created far more value in the last five years than all of the targeted therapies combined in AML. Now, the fact is that anthracyclines continue to be among the most used and most effective cancer therapies available. They're used in 32% of breast cancers, half of all AML patients, 70% of lymphomas, and actually 60% of all childhood cancers. So if you're looking for a true disruptor opportunity, the Anamycin story deserves your attention. What we believe we have is a safer, more effective anthracycline than has ever been possible. And it's enabling clinicians to treat with higher dosages and for a greater number of cycles than was ever thought feasible. And we aren't just filling an unmet need for more than half of AML patients. We're talking about potential uses far beyond just AML. Now, in this presentation, we're focusing just on the latest updates. So if you're new to Moleculin, I urge you to review our online presentations and watch our explanatory videos. With that said, though, just to hit the high spots of the Moleculin opportunity, the key takeaways from this slide are that unlike currently available anthracyclines, anamycin was designed to be 100% non-cardiotoxic. It avoids cross-resistance with the leading AML drugs, which means it has the potential to work when the others fail. And anamycin is patent-protected through 2040, which is a remarkably long remaining patent life for a Phase III cancer drug. And in part because targeted therapies have been such a disappointment, We still have almost 60% of the AML population without an acceptable treatment option. There is still an incredible unmet need in AML. So let me now ask our Senior Chief Medical Officer, Dr. Paul Waymack, to provide an update on patient data and our startup of the Phase III Miracle Trial. Paul?